Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Gilead Sciences
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A Study to Compare the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Myelofibrosis who were Treated with Ruxolitinib
To determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic subjects with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in Treatment Na�ve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
The primary objective of this study is to evaluate the antiviral efficacy (sustained virologic response [SVR]; defined as undetectable HCV RNA 24 weeks following treatment cessation) of 16 and 24 week...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for subjects with hepatitis C
To evaluate the efficacy of study treatment with sofosbuvir (SOF)/velpatasvir (VEL) FDC for 12 weeks as measured by the proportion of subjects with sustained virologic response 12 weeks after cessatio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
An investigational study to assess the safety and efficacy of a new investigational drug in subjects with compensated liver cirrhosis secondary to non-alcoholic steatohepatitis (NASH)
To evaluate whether simtuzumab (formerly referred to as GS-6624) can reduce portal venous pressure and incidence of clinical events in subjects with cirrhosis due to NASH.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, SL (Spain)
MAJ Il y a 4 ans
Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from zidovudine-containing backbone to truvada in HIV-1-infected patients on highly active antiretroviral therapy
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A long-term study to follow cirrhotic patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial
To assess the durability of SVR; To assess clinical progression or regression of liver disease, including the incidence of hepatocellular carcinoma (HCC) following SVR.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A study to evaluate the effects of the combination of 4 oral antiviral agents for the treatment of patients infected with the Hepatitis C Virus (HCV)
To evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < LLoQ 24 weeks post-treatment) of 30 mg or 90 mg GS-5885 when given with GS-9451, tegobuvir and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
This trial will test the drug filgotinib for the treatment of small bowel Crohn’s disease
The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission at Week 24
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
Study to Evaluate GS-5806 in Volunteers Infected with Respiratory Syncytial Virus
The primary objective of the study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with RSV-A Memphis 37b (RSV).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences Limited
MAJ Il y a 4 ans
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz
To determine if switching from Combivir® or AZT +3TC to a fixed-dose tablet of FTC/TDF leads to changes in absolute haemoglobin at 24 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
8
9
10
11
12
13
14
15
16
17
Suivant